Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 17:57:171-178.
doi: 10.1016/j.amsu.2020.07.015. eCollection 2020 Sep.

The role of multiparametric magnetic resonance imaging and magnetic resonance-guided biopsy in active surveillance for low-risk prostate cancer: A systematic review

Sultan Zaher Alshehri  1 , Omar Safar Alshahrani  2 , Nazal Ahmed Almsaoud  2 , Muhammad Ahmad Al-Ghamdi  2 , Abdulaziz Mohammed Alqahtani  2 , Muath Mohammed Almurayyi  1 , Ali Salem Autwdi  3 , Saeed Ahmed Al-Ghamdi  4 , Mohammed Mesadef Zogan  3 , Abdulrahim Mohammed Alamri  2
Affiliations
Review

The role of multiparametric magnetic resonance imaging and magnetic resonance-guided biopsy in active surveillance for low-risk prostate cancer: A systematic review

Sultan Zaher Alshehri et al. Ann Med Surg (Lond). .

Abstract

The performance of multiparametric magnetic resonance imaging (mpMRI) and subsequent biopsy in monitoring prostate cancer in men on active surveillance (AS) have not been defined clearly. In this systematic review, we aimed to review current literature about the usage of MRI examination in men with low-risk prostate cancer during active surveillance. For that, we searched seven databases to include all studies reporting magnetic resonance imaging in the AS of low-risk prostate cancer. We finally included 11 studies with 1237 patients included. Our results showed an adequate sensitivity and specificity of both modalities to detect disease progression; including disease upgrading and upstaging. However, the performance in the prediction of unfavorable disease was inferior to the detection of upgrading and upstaging. In terms of MRGB, the previous literature agreed on the superiority of using a combination of different biopsy schemes to get a better progression section. Noteworthy, mp-MRI and MRGB had a good predictive value limited to the first year, with TRUSGB showing a superior role in detecting patients with a GS ≥ 7, after that. In conclusion, both of mpMRI and MRGB have shown an adequate performance on assessing disease progression in the AS of low-risk prostate cancer patients. They can be used for disease staging and grading for successful treatment planning.

Keywords: Active surveillance; MRGB; MRI; Prostate cancer.

PubMed Disclaimer

Conflict of interest statement

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Figures

Fig. 1
Fig. 1
PRISMA flowchart of study search and selection process.
See this image and copyright information in PMC

References

    1. UPST Force. Screening for prostate cancer: US preventive services task force recommendation statement. Ann. Intern. Med. 2008;149(3):185. - PubMed
    1. Zhou C.K., Check D.P., Lortet‐Tieulent J., Laversanne M., Jemal A., Ferlay J. Prostate cancer incidence in 43 populations worldwide: an analysis of time trends overall and by age group. Int. J. Canc. 2016;138(6):1388–1400. - PMC - PubMed
    1. Hamdy F.C., Donovan J.L., Lane J., Mason M., Metcalfe C., Holding P. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N. Engl. J. Med. 2016;375:1415–1424. - PubMed
    1. Dhanasekaran S.M., Barrette T.R., Ghosh D., Shah R., Varambally S., Kurachi K. Delineation of prognostic biomarkers in prostate cancer. Nature. 2001;412(6849):822–826. - PubMed
    1. Loeb S., Vellekoop A., Ahmed H.U., Catto J., Emberton M., Nam R. Systematic review of complications of prostate biopsy. Eur. Urol. 2013;64(6):876–892. - PubMed